| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0905 | Bb-0322703 | Novel potent TRPM8 antagonist (IC 50 1.25 ± 0.26 μM) |
|
| DCC0906 | bb-78484 | Potent inhibitor of LpxC |
|
| DCC0907 | Bb-83698 Featured | BB-83698 is a peptide deformylase inhibitor and potent antimicrobial with excellent activity against streptococci and Moraxella catarrhalis strains. |
|
| DCC0908 | Bbb_26580140 | Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
| DCC0909 | Bbh-chal | Novel potent apoptotic inducer of human leukaemia cells by activation of the extrinsic pathway and the generation of reactive oxygen species |
|
| DCC0910 | Bc12-4 | Novel potent inhibitor of IL-2 secretion, demonstrating potent immunomodulatory activity |
|
| DCC0911 | Bc1464 | Novel FBXO7/PINK1 interaction antagonist, abrogating FBXO7 and PINK1 association, leading to increased cellular PINK1 concentrations and activities, and limiting mitochondrial damage |
|
| DCC0912 | bce-001 | Memory Enhancer and Free Radical Scavenger |
|
| DCC0913 | Bche Inhibitor 1 | Novel butyrylcholinesterase inhibitor (BChEi) for the treatment of canine cognitive dysfunction |
|
| DCC0914 | Bc-k01 | Novel inhibitor of the KRS-67LR interaction |
|
| DCC0915 | Bcl2 Degrader C5 | Novel potent and selective degrader of Bcl-2 |
|
| DCC0916 | Bcl-2 Inhibitor Pdf | Novel efficient Bcl-2 inhibitor, exhibiting high specificity and stabilizing effect toward G-quadruplexes |
|
| DCC0917 | Bcl-2 Inhibitor S1 | Novel pan-Bcl-2 family inhibitor, upregulating the BH3-only protein Noxa, which inhibits Mcl-1, inducing autophagy through (ER) stress and disruption of the interaction of Beclin 1 with Bcl-2 |
|
| DCC0918 | Bcl6-protac-15 | Novel B-Cell Lymphoma 6 (BCL6) PROTAC |
|
| DCC0919 | Bcn-e-bcn | Novel Cell-Permeable Probe for the Identification of Protein Sulfenic Acids |
|
| DCC0920 | Bcn-peg6-oh | Clearing cycloalkyne for click reaction with Azido-Warfarin WN3 or other Azido-containing drugs |
|
| DCC0921 | bcr-abl Inhibitor 9b | Novel highly potent inhibitor of breakpoint cluster region-abelson kinase (Bcr-Abl) including the T315I mutant |
|
| DCC0922 | Bcr-abl-in-y9 | Novel Bcr-Abl inhibitor, potently inhibited Bcr-AblWT and Bcr-AblT315I kinases with IC 50 of 0.043 μM and 0.17 μM, respectively |
|
| DCC0923 | bd-1008 | Potent and selective |
|
| DCC0924 | bddpm | Novel small molecule PTP1B inhibitor |
|
| DCC0925 | Bdf-9148 | Sodium channel enhancer |
|
| DCC0926 | Bdm14471 | Potent and selective hydroxamate PfAM1 inhibitor |
|
| DCC0927 | Bdm31343 | Novel EthR inhibitor, boosting antituberculous activity of ethionamide |
|
| DCC0928 | Bdm31369 | Novel activator of ethionamide |
|
| DCC0929 | Bdm31827 | Novel EthR inhibitor and ethionamide booster |
|
| DCC0930 | Bdm41906 | Novel specific bona fide EthR-inhibitor, boosting ETH 4 times in an intravenously infected TB mice model |
|
| DCC0931 | Bdoia383 | Novel CBP/p300 Bromodomains inhibitor, binding BRD4 almost identical to SGC-CBP30 |
|
| DCC0932 | beclomethasone 17-monopropionate | Active metabolite of beclomethasone dipropionate |
|
| DCC0933 | Behenyl Palmitate | Fatty Ester for Lipid Research |
|
| DCC0934 | Bemppox | Novel potent and specific inhibitor of dog gastric lipase (DGL) |
|
